fingolimod hydrochloride has been researched along with Chronic Disease in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Butler, E; Butzkueven, H; Buzzard, K; Eichau, S; Girard, M; Hodgkinson, S; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Monif, M; Oh, J; Prevost, J; Skibina, O; van der Walt, A; Van Pesch, V; Zhong, M | 1 |
| Fujita, H; Ikumi, N | 1 |
| Hirt, SW; Lehle, K; Puehler, T; Schmid, C; von Suesskind-Schwendi, M | 1 |
| Koch, M; Nashan, B; Poehnert, D | 1 |
| Correale, J; Gaitán, MI | 1 |
| Altman, JD; Moseley, NB; Premenko-Lanier, M; Pruett, ST; Romagnoli, PA | 1 |
| Baumann, M; Heemann, U; Liu, S; Lutz, J; Roos, M; Schmaderer, C; Strobl, M | 1 |
| Fujii, T; Watanabe, M | 1 |
| Aliaga, C; Amin, S; Baab, KT; Broeg, K; Desai, D; Dewey, A; Fox, T; Hirsch, L; Jarbadan, NR; Kester, M; Li, Y; Liao, A; Liao, J; Liu, X; Loughran, K; Loughran, TP; Rogers, A; Ryland, L; Shah, MV; Tan, SF; Wang, HG; Watters, R; Yang, J; Zhang, LQ | 1 |
| Chabwine, JN; Démonet, JF; du Pasquier, RA; Hirt, L; Kuntzer, T; Michel, P; Rossetti, AR; Schluep, M; Vingerhoets, FG | 1 |
| Koshiba, T; Pirenne, J; Rutgeerts, O; Van Damme, B; Waer, M | 1 |
| Heemann, U; Liu, S; Lutz, J; Ouyang, N; Song, E; Wang, M | 1 |
| Enosawa, S; Fukuchi, K; Hakamata, Y; Iwanami, S; Kaneko, T; Kishi, T; Kobayashi, E; Kudou, S; Kuriyama, K; Matsumoto, K; Morishita, Y; Murakami, T; Shimizu, H; Takahashi, M; Takeyoshi, I; Yasue, T | 1 |
| Ahn, KO; Bang, BK; Choi, BS; Kim, J; Kim, JS; Kim, JY; Kim, YS; Li, C; Lim, SW; Yang, CW; Yang, HJ | 1 |
| Brinkmann, V; Clarkson, MR; Fernandes, S; Habicht, A; Henderson, J; Jurewicz, M; Sayegh, MH; Yang, J; Yuan, X | 1 |
15 other study(ies) available for fingolimod hydrochloride and Chronic Disease
| Article | Year |
|---|---|
Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Topics: Chronic Disease; Cladribine; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2023 |
Generalized pustular psoriasis occurring in a patient with multiple sclerosis during treatment with fingolimod.
Topics: Chronic Disease; Etretinate; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Psoriasis; Skin Diseases, Vesiculobullous | 2023 |
Early administration of FTY720 prevents chronic airway as well as vascular destruction in experimental rat lung transplantation.
Topics: Acute Disease; Animals; Bronchiolitis Obliterans; Chronic Disease; Drug Administration Schedule; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Lung; Lung Transplantation; Lymphocytes; Male; Propylene Glycols; Rats; Rats, Inbred F344; Rats, Inbred WKY; Sclerosis; Sphingosine; Time Factors; Vascular Diseases | 2013 |
Effects of FTY720 on peripheral blood lymphocytes and graft infiltrating cells in a rat model of chronic renal allograft rejection.
Topics: Animals; B-Lymphocytes; Chronic Disease; Disease Models, Animal; Fingolimod Hydrochloride; Graft Rejection; Immunity, Cellular; Immunity, Humoral; Kidney Transplantation; Rats; T-Lymphocytes | 2016 |
Comment on extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
Topics: Chronic Disease; Fingolimod Hydrochloride; Humans; Leukoencephalopathy, Progressive Multifocal; Recurrence; White Matter | 2017 |
Transient FTY720 treatment promotes immune-mediated clearance of a chronic viral infection.
Topics: Animals; Chronic Disease; Fingolimod Hydrochloride; Lymphocytic Choriomeningitis; Lymphocytic choriomeningitis virus; Lymphopenia; Mice; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; T-Lymphocytes; Time Factors | 2008 |
Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
Topics: Animals; Chronic Disease; Cyclosporine; Drug Therapy, Combination; Everolimus; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Immunosuppressive Agents; Kidney Transplantation; Propylene Glycols; Rats; Rats, Inbred F344; Rats, Inbred Lew; Sirolimus; Sphingosine; Transplantation, Homologous | 2008 |
[An additional role of FTY720 in chronic colitis].
Topics: Animals; CD4-Positive T-Lymphocytes; Chronic Disease; Colitis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Mice, SCID; Propylene Glycols; Sphingosine; T-Lymphocytes | 2009 |
Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia.
Topics: Animals; Apoptosis; Blotting, Western; Cell Proliferation; Chronic Disease; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Killer Cells, Natural; Leukemia; Male; Myeloid Cell Leukemia Sequence 1 Protein; Propylene Glycols; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Inbred F344; RNA, Small Interfering; Sphingosine | 2011 |
[Neurology].
Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brain Stimulation; Dopamine Agonists; Epilepsy; Fingolimod Hydrochloride; Genetic Therapy; Humans; Immunosuppressive Agents; Ischemic Attack, Transient; Multiple Sclerosis; Muscular Diseases; Neurology; Parkinson Disease; Phenylenediamines; Polyneuropathies; Propylene Glycols; Sphingosine; Stroke; Treatment Outcome; Valproic Acid | 2012 |
FTY720, an immunosuppressant that alters lymphocyte trafficking, abrogates chronic rejection in combination with cyclosporine A.
Topics: Animals; Chronic Disease; Complement C3; Coronary Vessels; Cyclosporine; Drug Therapy, Combination; Endothelium, Vascular; Fingolimod Hydrochloride; Graft Rejection; Heart Transplantation; Immunoglobulin G; Immunohistochemistry; Immunosuppressive Agents; Lymphocyte Subsets; Lymphocytes; Male; Monocytes; Myocardium; Propylene Glycols; Rats; Sphingosine | 2003 |
Protective effects of FTY720 on chronic allograft nephropathy by reducing late lymphocytic infiltration.
Topics: Animals; Chronic Disease; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; In Situ Nick-End Labeling; Kidney Transplantation; Lymphocytes; Male; Propylene Glycols; Rats; Rats, Inbred F344; Sphingosine; Transplantation, Homologous | 2004 |
KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts.
Topics: Animals; Bradycardia; Chemotaxis, Leukocyte; Chronic Disease; Cyclosporine; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Guinea Pigs; Heart Rate; Heart Transplantation; Immunosuppressive Agents; Male; Molecular Structure; Propylene Glycols; Rats; Rats, Inbred F344; Rats, Inbred Lew; Rats, Inbred Strains; Rats, Wistar; Skin Transplantation; Sphingosine; Sulfhydryl Compounds; Transplantation, Heterotopic; Transplantation, Homologous | 2005 |
Effect of FTY720 on chronic cyclosporine nephropathy in rats.
Topics: Angiotensin II; Animals; Chronic Disease; Cyclosporine; Extracellular Matrix Proteins; Fibrosis; Fingolimod Hydrochloride; Immunosuppressive Agents; Kidney; Kidney Diseases; Lymphocytes; Macrophages; Male; Osteopontin; Propylene Glycols; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sialoglycoproteins; Sphingosine; T-Lymphocytes; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
Novel insights into the mechanism of action of FTY720 in a transgenic model of allograft rejection: implications for therapy of chronic rejection.
Topics: Adoptive Transfer; Animals; Apoptosis; CD4-Positive T-Lymphocytes; Chemotaxis, Leukocyte; Chronic Disease; Cytokines; Disease Models, Animal; Fingolimod Hydrochloride; Flow Cytometry; Graft Rejection; Heart Transplantation; Immunohistochemistry; Immunologic Memory; Immunosuppressive Agents; Lymphocyte Activation; Mice; Mice, Transgenic; Propylene Glycols; Receptors, Antigen, T-Cell; Skin Transplantation; Sphingosine; Transplantation, Homologous | 2006 |